MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

MDT

98.5

+2.11%↑

A

146.08

-0.25%↓

VEEV

218.2

-4.44%↓

HQY

85.69

+1.95%↑

NEOG

9.39

+2.4%↑

Search

Myomo Inc

Slēgts

0.91 -3.19

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.9

Max

0.95

Galvenie mērījumi

By Trading Economics

Ienākumi

969K

-3.7M

Pārdošana

438K

10M

Peļņas marža

-36.3

Darbinieki

184

EBITDA

1.1M

-3.1M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+486.73% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2026. g. 9. marts

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

5.1M

38M

Iepriekšējā atvēršanas cena

4.1

Iepriekšējā slēgšanas cena

0.91

Myomo Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. janv. 22:41 UTC

Iegādes, apvienošanās, pārņemšana

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

2026. g. 15. janv. 00:00 UTC

Peļņas

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

2026. g. 14. janv. 23:47 UTC

Tirgus saruna

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

2026. g. 14. janv. 23:44 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

2026. g. 14. janv. 23:39 UTC

Tirgus saruna

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

2026. g. 14. janv. 23:32 UTC

Tirgus saruna

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

2026. g. 14. janv. 22:56 UTC

Iegādes, apvienošanās, pārņemšana

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

2026. g. 14. janv. 22:53 UTC

Iegādes, apvienošanās, pārņemšana

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

2026. g. 14. janv. 22:17 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 14. janv. 22:17 UTC

Tirgus saruna

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

2026. g. 14. janv. 22:09 UTC

Peļņas

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

2026. g. 14. janv. 22:08 UTC

Peļņas

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

2026. g. 14. janv. 22:08 UTC

Peļņas

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

2026. g. 14. janv. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

2026. g. 14. janv. 21:53 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

2026. g. 14. janv. 21:52 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Announces Positive Profit Alert for 2025

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

Citigroup Acting as Financial Advisor to WuXi XDC

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: Aims to Keep Listing Status of BioDlink

2026. g. 14. janv. 21:51 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

2026. g. 14. janv. 21:50 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2026. g. 14. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 14. janv. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC: BioDlink Offer to Cost HK$2.79B

2026. g. 14. janv. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

2026. g. 14. janv. 21:48 UTC

Iegādes, apvienošanās, pārņemšana

WuXi XDC Makes Cash Offer for BioDlink International

2026. g. 14. janv. 21:13 UTC

Tirgus saruna

Oil Retreats Late After Trump Comments on Iran -- Market Talk

2026. g. 14. janv. 20:30 UTC

Tirgus saruna
Peļņas

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

2026. g. 14. janv. 20:13 UTC

Tirgus saruna

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

2026. g. 14. janv. 20:08 UTC

Tirgus saruna

Oil Futures Extend Rally on Iran Tensions -- Market Talk

2026. g. 14. janv. 19:33 UTC

Tirgus saruna

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

2026. g. 14. janv. 19:06 UTC

Tirgus saruna
Peļņas

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Salīdzinājums

Cenas izmaiņa

Myomo Inc Prognoze

Cenas mērķis

By TipRanks

486.73% augšup

Prognoze 12 mēnešiem

Vidējais 5.75 USD  486.73%

Augstākais 10 USD

Zemākais 4 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myomo Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

5 ratings

5

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myomo Inc

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
help-icon Live chat